Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS)

Historical Holders from Q1 2025 to Q3 2025

Symbol
KLRS on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
22,926,692
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
13,222,873
Holdings value
$76,428,251
% of all portfolios
0%
Number of holders
31
Number of buys
17
Number of sells
11
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Samsara BioCapital, L.P. 56% -7.7% $65,674,656 +$7,632,885 12,953,581 +13% Srinivas Akkaraju 22 Dec 2025
GILEAD SCIENCES, INC. 3.9% $5,807,882 723,273 GILEAD SCIENCES, INC. 18 Mar 2025
Invus Global Management, LLC 1.5% $955,141 282,586 Invus Public Equities, L.P. 30 Jun 2025
EcoR1 Capital, LLC 1.1% $1,619,796 201,718 EcoR1 Capital, LLC 31 Mar 2025
As of 30 Sep 2025 Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 13,222,873 shares of 22,926,692 outstanding shares and own 58% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) own 58% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
SAMSARA BIOCAPITAL, LLC 50% 11,448,081 0% 8.6% $66,169,908
TANG CAPITAL MANAGEMENT LLC 1.8% 418,241 +16% 0.09% $2,417,433
Siren, L.L.C. 1.4% 318,264 +13% 0.07% $1,839,566
Woodline Partners LP 1.1% 241,102 0.01% $1,393,570
VANGUARD GROUP INC 0.89% 203,051 +56% 0% $1,173,635
RENAISSANCE TECHNOLOGIES LLC 0.49% 112,751 +17% 0% $651,701
Redmile Group, LLC 0.36% 82,955 0% 0.05% $479,480
GEODE CAPITAL MANAGEMENT, LLC 0.28% 64,551 +153% 0% $373,147
BlackRock, Inc. 0.18% 40,379 +5.8% 0% $233,391
Squarepoint Ops LLC 0.18% 40,173 -32% 0% $232,200
Belpointe Asset Management LLC 0.17% 40,000 0.01% $231,200
Fortis Capital Advisors, LLC 0.17% 40,000 0.04% $231,200
MILLENNIUM MANAGEMENT LLC 0.11% 24,923 -54% 0% $144,055
MORGAN STANLEY 0.11% 24,918 +1169% 0% $144,026
STATE STREET CORP 0.1% 22,610 +111% 0% $130,686
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.1% 22,500 0% $130,050
GOLDMAN SACHS GROUP INC 0.1% 22,465 0% $129,848
RBF Capital, LLC 0.08% 17,391 0% 0% $100,520
MARSHALL WACE, LLP 0.06% 14,115 0% 0% $81,585
Johnson Financial Group, Inc. 0.04% 10,000 0% $57,800
FMR LLC 0.03% 7,806 0% 0% $45,119
UBS Group AG 0.02% 5,252 +28% 0% $30,357
FEDERATED HERMES, INC. 0% 578 -8.8% 0% $3,341
Strengthening Families & Communities, LLC 0% 268 0% $1,549
BANK OF AMERICA CORP /DE/ 0% 217 -21% 0% $1,254

Institutional Holders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 13,222,873 $76,428,251 +$1,455,561 $5.78 31
2025 Q2 13,362,268 $35,677,274 -$2,639,076 $2.67 29
2025 Q1 13,874,350 $111,411,096 +$111,410,077 $8.03 31